Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Dennis J. Selkoe, M.D.

Co-Author

This page shows the publications co-authored by Dennis Selkoe and Ulf Dettmer.
Connection Strength

5.978
  1. Loss of native a-synuclein multimerization by strategically mutating its amphipathic helix causes abnormal vesicle interactions in neuronal cells. Hum Mol Genet. 2017 09 15; 26(18):3466-3481.
    View in: PubMed
    Score: 0.771
  2. Corrigendum: Parkinson-causing a-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. Nat Commun. 2015 Jul 30; 6:8008.
    View in: PubMed
    Score: 0.665
  3. KTKEGV repeat motifs are key mediators of normal a-synuclein tetramerization: Their mutation causes excess monomers and neurotoxicity. Proc Natl Acad Sci U S A. 2015 Aug 04; 112(31):9596-601.
    View in: PubMed
    Score: 0.663
  4. Parkinson-causing a-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. Nat Commun. 2015 Jun 16; 6:7314.
    View in: PubMed
    Score: 0.660
  5. In vivo cross-linking reveals principally oligomeric forms of a-synuclein and ß-synuclein in neurons and non-neural cells. J Biol Chem. 2013 Mar 01; 288(9):6371-85.
    View in: PubMed
    Score: 0.558
  6. Upregulation of Cellular Palmitoylation Mitigates a-Synuclein Accumulation and Neurotoxicity. Mov Disord. 2021 02; 36(2):348-359.
    View in: PubMed
    Score: 0.239
  7. A Stearoyl-Coenzyme A Desaturase Inhibitor Prevents Multiple Parkinson Disease Phenotypes in a-Synuclein Mice. Ann Neurol. 2021 01; 89(1):74-90.
    View in: PubMed
    Score: 0.239
  8. Rapid Alpha-Synuclein Toxicity in a Neural Cell Model and Its Rescue by a Stearoyl-CoA Desaturase Inhibitor. Int J Mol Sci. 2020 Jul 22; 21(15).
    View in: PubMed
    Score: 0.235
  9. Vesicle trafficking and lipid metabolism in synucleinopathy. Acta Neuropathol. 2021 04; 141(4):491-510.
    View in: PubMed
    Score: 0.234
  10. Parkinson's disease: proteinopathy or lipidopathy? NPJ Parkinsons Dis. 2020; 6:3.
    View in: PubMed
    Score: 0.226
  11. Parkinson's disease: proteinopathy or lipidopathy? NPJ Parkinsons Dis. 2020 Jan 03; 6(1):3.
    View in: PubMed
    Score: 0.226
  12. Cell models of lipid-rich a-synuclein aggregation validate known modifiers of a-synuclein biology and identify stearoyl-CoA desaturase. Proc Natl Acad Sci U S A. 2019 10 08; 116(41):20760-20769.
    View in: PubMed
    Score: 0.222
  13. Lipidomic Analysis of a-Synuclein Neurotoxicity Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment. Mol Cell. 2019 03 07; 73(5):1001-1014.e8.
    View in: PubMed
    Score: 0.210
  14. Abrogating Native a-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson's Disease. Neuron. 2018 10 10; 100(1):75-90.e5.
    View in: PubMed
    Score: 0.208
  15. New insights into cellular a-synuclein homeostasis in health and disease. Curr Opin Neurobiol. 2016 Feb; 36:15-22.
    View in: PubMed
    Score: 0.167
  16. Purification of a-synuclein from human brain reveals an instability of endogenous multimers as the protein approaches purity. Biochemistry. 2015 Jan 20; 54(2):279-92.
    View in: PubMed
    Score: 0.160
  17. A new method for quantitative immunoblotting of endogenous a-synuclein. PLoS One. 2013; 8(11):e81314.
    View in: PubMed
    Score: 0.148
  18. Defining the native state of a-synuclein. Neurodegener Dis. 2014; 13(2-3):114-7.
    View in: PubMed
    Score: 0.147
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.